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ndostatin (ES) is a fragment of collagen XVIII that
possesses antiangiogenic activity. To gain insight into
ES-mediated signaling, we studied the effects of ES
RNA on 
 
Xenopus
 
 embryogenesis and observed develop-
mental abnormalities consistent with impaired Wnt signaling.
ES RNA blocked the axis duplication induced by 
 
 
 
-catenin,
partially suppressed Wnt-dependent transcription, and
stimulated degradation of both wild-type and “stabilized”
forms of 
 
 
 
-catenin, the latter suggesting that ES signaling
does not involve glycogen synthase kinase 3. Moreover, ES
uses a pathway independent of the Siah1 protein in targeting
 
 
 
-catenin for proteasome-mediated degradation. ES failed
E
 
to suppress the effects of T cell–speciﬁc factor (TCF)-VP16
(TVP), a constitutive downstream transcriptional activator
that acts independently of 
 
 
 
-catenin. Importantly, these
data were replicated in endothelial cells and also in the
DLD-1 colon carcinoma cells with the mutated adenomatous
polyposis coli protein. Finally, suppression of endothelial
cell migration and inhibition of cell cycle by ES were reversed
by TVP. Though high levels of ES were used in both the
 
Xenopus
 
 and endothelial cell studies and the effects on
 
 
 
-catenin signaling were modest, these data argue that at
pharmacological concentrations ES may impinge on Wnt
signaling and promote 
 
 
 
-catenin degradation.
 
Introduction
 
Angiogenesis, the formation of new capillaries through
sprouting, is the primary process responsible for tumor
neovascularization (Hanahan and Folkman, 1996; Carmeliet,
2000). This process depends on the balance between the
effects of pro- and antiangiogenic molecules. Endostatin
(ES),* a COOH-terminal fragment of collagen XVIII, is a
recently described antiangiogenic factor (O’Reilly et al.,
1997). Exogenous recombinant ES inhibits tumor growth
in several animal models (O’Reilly et al., 1997; Blezinger
et al., 1999; Dhanabal et al., 1999a; Yoon et al., 1999;
Sauter et al., 2000; Yokoyama et al., 2000; Feldman et al.,
2001), and its usefulness for human cancer treatment is
being assessed in clinical trials (Herbst et al., 2001). In
vitro, ES blocks endothelial cell migration, promotes apoptosis,
and induces cell cycle arrest (Dhanabal et al., 1999a,b,c).
Currently, which of these effects are most relevant in vivo
when ES is administered for tumor therapy is unclear.
Both collagen XVIII and ES are involved in many aspects
of embryonic development. Collagen XVIII is present in the
tubular kidney basement membrane and is necessary for ureter
morphogenesis (Lin et al., 2001). ES has been purified from
the cultured supernatant of a kidney ureteric bud cell line
and shown to modulate the mesenchymal–epithelial transition
(Yung, J., T. Novak, M. Dhanabal, V. Sukhatme, and J.
Barasch.  2000. Endostatin stimulates growth of epithelial
precursors. American Society of Nephrology Annual Meeting,
Toronto, Ontario, Canada. A2187. [Abstr.].). Moreover, we
have shown recently that ES blocks renal branching morpho-
genesis and tubulogenesis (Karihaloo et al., 2001; Karumanchi
et al., 2001). A splice mutation in human collagen XVIII
that leads to a truncated protein lacking the ES fragment
occasionally causes abnormalities in the renal collecting duct
(Knobloch syndrome) (Sertie et al., 2000). The major pheno-
type in this disease is a failure of neural tube closure and
vitreal and retinal degradation. At present, the physiological
role of collagen type XVIII in control of vasculogenesis
remains unclear. Nevertheless, mice lacking collagen type
XVIII gene display retinal vessel abnormality (Fukai et al.,
2002). In 
 
Caenorhabditis elegans
 
, loss of the ES domain in the
 
cle-1
 
 gene, a collagen XVIII homologue, results in multiple
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cell migration and axon guidance defects (Ackley et al., 2001).
Besides ES, the collagen XVIII gene contains an alternatively
spliced fragment encoding a domain similar to the extracellu-
lar region of the frizzled (Frz) family members (Zatterstrom et
al., 2000). Since Frz proteins function as cell surface receptors
for secreted Wnt ligands (Bhanot et al., 1996; Wang et al.,
1996; Zatterstrom et al., 2000), the structure of collagen
XVIII suggests its possible involvement in Wnt signaling.
Wnt signaling pathways play important roles in the regula-
tion of cellular proliferation, differentiation, motility, and
morphogenesis (Wodarz and Nusse, 1998; Akiyama, 2000;
Bienz and Clevers, 2000; Polakis, 2000). Signaling by the Frz
receptors results in activation of the cytoplasmic Dishevelled
(Dsh) proteins. Dsh antagonizes the effects of glycogen syn-
thase kinase (GSK)3, thus leading to 
 
 
 
-catenin stabilization
(Cadigan and Nusse, 1997; Gumbiner, 1997; Sokol, 1999).
Stability of 
 
 
 
-catenin is a critical point in Wnt signaling that
is regulated by many cytoplasmic proteins including Axin,
Frat/GBP, protein phosphatase 2A, adenomatous polyposis
coli (APC), and GSK3 (Yost et al., 1996, 1998; Zeng et al.,
1997; Kishida et al., 1999; Smalley et al., 1999; Ikeda et al.,
2000; Itoh et al., 2000; Polakis, 2000). Stabilized 
 
 
 
-catenin
translocates to the nucleus where it binds to members of the
T cell–specific factor (TCF)/lymphoid enhancer binding fac-
tor 1 transcription factor family and stimulates transcription
of the target genes including c-Myc, cyclin D, and Siamois
(Peifer and Polakis, 2000; Polakis, 2000).
Little is known about ES signal transduction. We have re-
ported recently that glypicans are low affinity ES receptors
critically important in mediating ES activities, such as the
inhibitory effects on both endothelial cell and renal tubular
branching morphogenesis (Karihaloo et al., 2001; Karuman-
chi et al., 2001). Although ES has been reported to activate
tyrosine kinase signaling through the Shb adaptor protein
(Dixelius et al., 2000), it remains to be defined how ES sig-
nals are transduced inside the cell. To gain insight into sig-
nal transduction pathways driven by ES, we used 
 
Xenopus
 
embryogenesis as a model system that is well characterized
with respect to several signaling pathways (Harland and
Gerhart, 1997; Kimelman and Griffin, 2000). Here, we
show that at high concentrations ES can antagonize the Wnt
pathway in 
 
Xenopus
 
 embryos and in mammalian cells. Fur-
thermore, our results suggest that ES may inhibit endothelial
cell migration and arrest the cell cycle by inhibiting TCF-
dependent transcription.
 
Results
 
ES causes specific developmental defects in 
 
Xenopus
 
 embryos
 
To gain insight into signal transduction pathways that in-
volve ES, we used overexpression analysis in early 
 
Xenopus
 
embryos. This in vivo system is well suited for the analysis
of several pathways, including FGF, transforming growth
Figure 1. Developmental effects of ES in Xenopus 
embryos. Four to eight cell embryos were injected 
into the animal side of one ventral (V) blastomere (A) 
with wild-type or mutated ES RNAs (2 ng each) and 
cultured for 48 h at room temperature to assess 
cement gland development. (B) Summary of the data. 
(C) Embryos injected with ES RNA develop ectopic 
cement glands (arrowheads). (D) Embryos injected 
with RNA encoding an NH2-terminal deletion construct 
(ES-m) are indistinguishable from uninjected embryos. 
(E) Protein expression levels in embryos injected with 
ES and ES-m RNAs assessed by anti-ES antibody. 
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factor-
 
 
 
,
 
 
 
and Wnt signaling, since activation of these path-
ways results in developmental changes that are easily detect-
able at the morphological level. To analyze the effects of ES
in frog embryos, we constructed a recombinant form of ES,
which contains a signal peptide allowing secretion and does
not require proteolytic processing (Karumanchi et al.,
2001). In vitro synthesized mRNAs encoding wild-type and
mutated forms of ES were microinjected into a single ani-
mal ventral or dorsal blastomere of 
 
Xenopus
 
 embryos at the
4–8-cell stage. Injected embryos were cultured, and their
development was closely monitored. Starting at neurula
stages, 72.7% of embryos injected ventrally with 2 ng ES
RNA developed an ectopic cement gland, an anterior ecto-
dermal organ that forms near the future mouth of the tad-
pole (
 
n
 
 
 
  
 
55) (Fig. 1), whereas dorsal injection resulted in
eye defects (data not shown). In contrast, mutated ES with
an NH
 
2
 
-terminal deletion (ES-m) failed to interfere with
normal development (Fig. 1, B and D). Both ES and ES-m
proteins were expressed at comparable levels (Fig. 1 E).
These defects are similar to those obtained by overexpres-
sion of GSK3
 
 
 
, an inhibitor of Wnt signaling (Itoh et al.,
1995), or partial depletion of 
 
 
 
-catenin, a key mediator of
Wnt signal transduction (Heasman et al., 2000). Thus, the
phenotype induced by ES in 
 
Xenopus
 
 embryos suggests that
ES might antagonize Wnt signaling.
Since several inhibitors of 
 
 
 
-catenin signaling, including
Axin and a dominant negative TCF, are known to inhibit
dorsal development (Gumbiner, 1997; Sokol, 1999), we as-
sessed the effect of ES after injection of RNA in dorsovegetal
blastomeres. No significant suppression of dorsal structures
was observed (unpublished data), suggesting that the signal-
ing pathway activated by ES differs from the canonical Wnt-
dependent mechanisms for 
 
 
 
-catenin degradation.
 
ES impinges on Wnt signaling
 
To evaluate whether ES can modulate the Wnt pathway,
we assessed its effect on 
 
 
 
-catenin activity. 
 
 
 
-catenin is an
essential mediator of Wnt signaling and is known to in-
duce a secondary axis when overexpressed in 
 
Xenopus
 
 em-
bryos (Guger and Gumbiner, 1995). Injection of 
 
 
 
-cate-
nin RNA into a ventral blastomere of 4-cell embryos
resulted in a significant percentage of embryos with dupli-
cated head-containing body axes (53%, total number 
 
 
 
45) (Fig. 2). In contrast, most embryos coinjected with ES
RNA (86%, 
 
n 
 
  
 
29) developed only a single axis or a par-
tial secondary axis with trunk and tail structures but with-
out head, thus demonstrating the inhibitory activity of
ES. An ES deletion mutant (ES-m) did not have this ac-
tivity (81% of embryos had secondary axes; 
 
n 
 
  
 
25). Sim-
ilarly, axis-inducing activity of Wnt8 was also suppressed
Figure 2. ES inhibits  -catenin–dependent 
signaling. (A) Embryos were injected into one 
ventral vegetal blastomere with 50 pg of  -catenin 
( -cat) RNA with or without 2 ng of ES or ES-m 
RNA. Secondary axis induction was assessed after 
48 h culture at room temperature. (B) Luciferase 
activity was measured in embryos microinjected 
with the Siamois promoter–reporter construct 
(pSiaLuc). pSia-Luc activation by  -catenin was 
reduced by ES but not by ES-m. (C) The effect of ES 
on  -catenin signaling in endothelial cells. Transcriptional activation of the TOP-FLASH and FOP-FLASH reporters was measured in HUVECs 
transfected with indicated plasmids in the presence or absence ES or ES mutant (ES 3.1). Numbers show the amount of ES in  g/ml and the 
amount of transfected  -catenin plasmid per well of a 6-well plate. Cells were transfected with 0.8  g of each reporter plasmid. 
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by ES (unpublished data). These findings are consistent
with the hypothesis that ES functions as an inhibitor of
the Wnt pathway.
Next, we wanted to determine whether the suppression
of 
 
 
 
-catenin–mediated axis induction by ES results from
direct inhibition of early Wnt signal transduction or repre-
sents an effect of ES on non-Wnt signaling pathways
involved in axis determination later in development. There-
fore, we studied whether ES inhibits Wnt/
 
 
 
-catenin–
dependent transcriptional targets and analyzed the effect of
ES and ES-m on 
 
Siamois
 
 promoter activation by 
 
 
 
-catenin
(Fig. 2 B) or Wnt8 (data not shown). ES but not ES-m re-
duced 
 
Siamois
 
 promoter activation by 
 
 
 
-catenin (Fig. 2 B)
or Wnt8 (data not shown). Because 
 
Siamois
 
 is an immedi-
ate target for Wnt signaling (Brannon et al., 1997; Fan et
al., 1998), this result suggests that ES inhibits the Wnt/
 
 
 
-
catenin pathway in a direct manner.
We also examined whether the effects of ES in 
 
Xenopus
 
 em-
bryos could be reproduced in endothelial cells in which ES
activity was initially demonstrated (O’Reilly et al., 1997).
TOP-FLASH, a 
 
 
 
-catenin responsive reporter with multi-
merized TCF sites, but not the control FOP-FLASH construct
with mutated TCF sites (van de Wetering et al., 1991,
1996), was activated in human umbilical vein endothelial
cells (HUVECs), transiently transfected with a 
 
 
 
-catenin
plasmid (Fig. 2 C). At 5–20 
 
 
 
g/ml doses, ES repressed TOP-
FLASH activation in HUVECs by 30–60%. Lower ES doses
(100 ng/ml) produced similar inhibition in calf pulmonary
arterial endothelial (CPAE) cells (unpublished data). On the
other hand, ES with double point mutations, which lacks ac-
tivity in endothelial migration assays (ES3.1) (Karumanchi et
al., 2001), had no effect on promoter activation (Fig. 2 C).
Together, these experiments suggest that ES can inhibit the
Wnt pathway both in 
 
Xenopus
 
 embryos and endothelial cells.
Figure 3. Effects of ES in response to increasing Dsh and TVP activity. (A and B) Embryos were injected into one ventral vegetal blastomere 
as indicated with the following RNAs: TVP (0.7 pg), Dsh (0.7 ng); ES and ES-m (2 ng). (A) ES failed to inhibit TVP induced secondary axes. 
(B) The effect of ES constructs on secondary axes induced by Dsh and TVP. Total number of injected embryos varied from 14 to 70 per group. 
(C) The effect of ES on transcriptional activation of TOP-FLASH in response to Dsh and TVP. HUVECs were transfected with 0.4  g of TVP or 
empty vector in the presence (5 or 20  g/ml) or absence of ES. ES inhibited Dsh-mediated but not TVP-mediated activation of the reporter. 
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Figure 4. ES down-regulates  -catenin levels. (A) ES decreases steady state  -catenin levels in embryo lysates. Embryos were coinjected 
with Myc-tagged  -catenin ( -cat) or  N– -catenin ( N- -cat) RNAs (300 and 100 pg, respectively) and either wild-type or mutated ES 
RNA. At embryonic stages 8–8.5,  -catenin levels were analyzed by Western blotting with anti-Myc antibodies. ES but not ES-m 
reduced both  -catenin and  N– -catenin protein levels. (B) Effect of ES on  -catenin levels in HUVECs. ES (5 or 20  g/ml) but not 
mutant ES 3.1 (20  g/ml) reduced Flag– -catenin levels in transfected HUVECs. (C) ES down-regulates endogenous  -catenin in CPAE 
cells. Cells were incubated with indicated amounts of ES ( g/ml) for 24 h, and cell lysate were collected for western analysis. (D and E) 
ES blocks the signaling activity of stabilized  -catenin in Xenopus. Embryos were injected with 150–300 pg of  N– -catenin RNA and 
2 ng of ES or ES-m RNA as described in the Fig. 2 legend. (D) Suppression of secondary axes induced by  N– -catenin. (E) Summary of 
the data. (F) ES blocks the signaling activity of stabilized  -catenin in HUVECs. Transcriptional activation of TOP-FLASH in HUVECs 
transfected with 0.4  g of  -catenin S A mutant ( -SA) or empty vector in the presence or absence of 5–20  g/ml of ES. (G) ES down-
regulates TOP-FLASH in the colon cancer DLD-1 cells with constitutively high levels of  -catenin signaling. DLD-1 cells were 
transfected with 0.9  g of TOP-FLASH reporter plasmid and incubated in the presence (10 or 20  g/ml) or absence of ES. Cell lysates 
were collected 24 h after transfection for luciferase activity measurement.534 The Journal of Cell Biology | Volume 158, Number 3, 2002
 -catenin as a target for ES
The canonical Wnt pathway has been shown to involve sev-
eral molecular components, which function sequentially (Ca-
digan and Nusse, 1997; Sokol, 1999). Therefore, we tested
the ability of ES to block signal transduction at different levels
using both Xenopus embryos and endothelial cells. Injection
of TCF-VP16 (TVP) RNA, encoding NH2-terminally de-
leted Xtcf3 fused to the VP16 transcriptional activator (Von-
ica et al., 2000), resulted in axis duplication (Fig. 3). TVP
lacks the  -catenin binding site and is a constitutive transcrip-
tional activator that is independent of  -catenin (Vonica et
al., 2000). Importantly, ES failed to inhibit TVP-mediated
axis duplication (Fig. 3, A–B). In contrast, secondary axes in-
duced by Dsh, an upstream component of the pathway, were
inhibited by ES (Fig. 3 B). Similar data were obtained by
measuring TOP-FLASH reporter activation in HUVECs
(Fig. 3 C). These findings show that ES operates downstream
of or parallel to Dsh, possibly at the level of  -catenin.
Since ES strongly inhibited the function of  -catenin but
failed to modulate activity of TVP, we evaluated whether
 -catenin stability was affected by ES. Treatment with ES
but not with the mutated forms of ES decreased steady-
state levels of tagged  -catenin in both Xenopus embryos
and endothelial cells (Fig. 4, A and B). Moreover, endoge-
nous  -catenin was also down-regulated in endothelial cells
by ES (Fig. 4 C). These findings suggest that  -catenin may
be a target for ES.
Next, we asked whether the stable form of  -catenin, lack-
ing NH2-terminal phosphorylation sites ( N– -catenin
[Yost et al., 1996]), is affected by ES. NH2-terminal phos-
phorylation has been shown to be required for  -catenin deg-
radation (Yost et al., 1996), and  N- -catenin is insensitive
to upstream antagonists of Wnt signaling, such as GSK3 ,
APC, and axin (Peifer and Polakis, 2000). We found that ES
but not ES-m decreased expression of  N– -catenin (Fig. 4
A) and suppressed the ability of  N– -catenin to induce sec-
ondary axes in frog embryos (Fig. 4, D and E). Consistent
with these Xenopus data, ES reduced the TOP-FLASH acti-
vation induced by the stabilized S A  -catenin mutant ( -
SA) (Liu et al., 1999) in endothelial cells (Fig. 4 F). These
data indicate that ES modulates the Wnt pathway by regulat-
ing  -catenin stability via a novel GSK3-independent mech-
anism. Moreover, ES but not the ES mutant ES3.1 down-
regulated TOP-FLASH activity in DLD-1, colon cancer cells
carrying an APC mutation that results in constitutively high
 -catenin signaling (Morin et al., 1997) (Fig. 4 G). To-
gether, these observations suggest that ES works in a GSK3-
and an APC-independent manner.
The   TrCP protein associates with  -catenin through
recognition of specific NH2-terminal sites for GSK3 phos-
phorylation, thereby targeting it for ubiquitin-proteasome–
dependent degradation (Jiang and Struhl, 1998; Liu et al.,
1999; Maniatis, 1999). In CPAE cells,  -catenin levels were
decreased by  TrCP, whereas a dominant negative  TrCP
( N TrCP) interfered with this degradation pathway re-
sulting in upregulation of  -catenin (Fig. 5 A). ES decreased
 -catenin levels and TOP-FLASH activity in the presence of
 N TrCP, indicating that it can promote  -catenin degra-
dation even when the  TrCP function is blocked, lending
additional support for GSK3-independent action of ES.
A novel pathway for  -catenin degradation has been de-
scribed that involves Siah1, a human homologue of seven in
absentia (Della et al., 1993; Liu et al., 2001; Matsuzawa and
Reed, 2001). Since this degradation route is GSK3 and
TrCP independent, we explored a possible role for Siah1 in
ES signaling. In CPAE cells,  -catenin levels were down-
regulated by wild-type Siah1 and up-regulated by the domi-
nant negative Siah1 (Siah1-dR [Hu and Fearon, 1999]) con-
sistent with previous reports (Fig. 5 A). Importantly, ES still
decreased  -catenin levels and TOP-FLASH activity in cells
transfected with Siah1-dR (Fig. 5 A), demonstrating that
ES-mediated degradation of  -catenin does not depend
on Siah1. Nevertheless, MG132, a proteasome inhibitor
(Jensen et al., 1995), significantly decreased ES activity and
up-regulated   -catenin levels (Fig. 5 B), indicating that
ubiquitin-dependent proteolysis is involved.
Figure 5. ES effects on  -catenin are not mediated through  TrCP 
or Siah1. (A) CPAE cells were transfected with 0.4  g of myc– -catenin 
and 0.8  g of each Flag- TrCP, Flag- N TrCP, Flag-Siah1, or 
Flag–Siah1-dR, as indicated, in the presence (20  g/ml) or absence 
of ES. ES reduced transcriptional activation of TOP-FLASH by
 -catenin in the presence of dominant negative forms of  TrCP or 
Siah1.  -catenin levels were measured in the same experiment in 
the presence (20  g/ml) or absence of ES. (B) Proteasome inhibitor 
treatment reverses the effect of ES on  -catenin. CPAE cells were 
transfected with the Flag– -catenin and GFP plasmids. After 24 h, 
cells were incubated with ES (10  g/ml) and/or the proteasome 
inhibitor MG132 (MG) for 3 h as indicated. Cell lysates were 
collected for Western blotting with anti-Flag and anti-GFP antibodies. 
(C) ES effect on TOP-FLASH requires glypican 1. Transcriptional 
activity of TOP-FLASH was measured in glypican 1 antisense virus- 
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ES effects on  -catenin require glypican 1
Previously, we showed that glypicans function as low affinity
receptors for ES (Karumanchi et al., 2001). To test whether
glypicans are involved in the effect of ES on  -catenin sig-
naling (Fig. 5 C), we used the antisense approach. In
HUVECs stably infected with a glypican 1 antisense virus,
surface expression of glypican 1 is reduced by  80%
(Karumanchi et al., 2001). ES inhibited TOP-FLASH acti-
vation in control HUVECs but not in these HUVECs carry-
ing the antisense retrovirus. These data point to the impor-
tance of glypican 1 in ES signaling.
ES inhibits endothelial cell migration and entry into the 
S phase of the cell cycle by targeting LEF/TCF sites
The antiangiogenic activity of ES has been connected with its
ability to modulate endothelial cell migration and cause G1
arrest of the cell cycle (Dhanabal et al., 1999c). Whereas our
findings show that ES can decrease  -catenin stability and in-
hibit Wnt-dependent transcriptional targets, it is unclear
whether the effects of ES on endothelial cell migration or the
cell cycle are due to the modulation of the Wnt pathway.
Since TVP, a constitutive active transcriptional activator of
TCF-dependent transcription, acts in a  -catenin–indepen-
dent manner and ES down-regulates  -catenin, we asked
whether this reagent can rescue the inhibitory effects of ES
on endothelial cell migration and cell cycle progression.
HUVECs infected with a TVP-containing retrovirus
(TVP-HUVEC) express TVP in cell lysates (Fig. 6 A) and
reveal elevated TOP-FLASH reporter activity (Fig. 6 B). We
subsequently studied the effects of ES and TVP on endothe-
lial cell migration in the Boyden chamber assay in response
to the angiogenic factors VEGF and basic FGF (bFGF)
(Yamaguchi et al., 1999; Boilly et al., 2000). Interestingly,
in TVP-HUVECs, bFGF but not VEGF augmented the
migratory response compared with control vector-infected
HUVECs, suggesting that the effects of the two angiogenic
factors involve different signaling pathways. ES inhibited
both bFGF- and VEGF-induced migration of control
HUVECs but had no effect on TVP-HUVECs (Fig. 6 C).
This observation shows that TVP overcomes the block in
cell migration imposed by ES.
To evaluate whether TVP can reconstitute cell cycle pro-
gression blocked by ES, we performed cell cycle analysis us-
ing control HUVECs and TVP-HUVECs treated with the
combination of VEGF, bFGF, and ES. ES inhibited S phase
entry of control HUVECs stimulated by VEGF or bFGF
Figure 6. Activated TCF (TVP) reverses the inhibitory 
effects of ES on endothelial cell migration and cell 
cycle. For migration assays and cell cycle analysis, 
TVP-infected HUVECs (TVP-HUVEC) or empty virus-
infected HUVECs were used. TVP-HUVECs expressed 
Myc-TVP as detected by anti-Myc antibodies (A) and 
had elevated TOP-FLASH reporter activity (B). 
(C) Migration assays were performed in Boyden 
chambers with VEGF (20 ng/ml) or bFGF (20 ng/ml) as 
stimulants. ES (1  g/ml) had no effect on TVP-HUVECs. 
(D) FACS
® analysis of the cell cycle stage was 
performed with VEGF (20 ng/ml) or bFGF (20 ng/ml) as 
stimulants in the presence or absence of ES (20  g/ml). 
ES reduced the number of cells entering the S phase in 
control HUVECs but not in TVP-HUVECs.536 The Journal of Cell Biology | Volume 158, Number 3, 2002
(Fig. 6 D). However, no inhibitory effect of ES was detected
in TVP-HUVECs. Together, these results suggest that ES
targets transcription through LEF/TCF binding sites.
Discussion
Antiangiogenic properties of ES have been attributed to a
block in endothelial cell migration and cell cycle arrest
(Dhanabal et al., 1999a; Shichiri and Hirata, 2001), yet un-
derlying signal transduction pathways remain elusive. Using
both Xenopus embryos and mammalian cultured cells, this
study demonstrates that ES triggers GSK3-independent deg-
radation of  -catenin, a key mediator of Wnt signaling.
Both activities of ES, the block of  -catenin function and
inhibition of endothelial cell migration and S phase entry,
can be rescued by the downstream transcriptional activator
TVP, which acts independently of  -catenin. These findings
suggest that one effect of ES arises from its ability to down-
regulate Wnt signaling. Additionally, our results implicate
Wnt/ -catenin signaling in the regulation of endothelial cell
migration and cell cycle progression.
The major limitation of our gain of function experiments
is that they employ fairly high concentrations of ES and that
only modest effects on  -catenin are observed. However, our
experiments are controlled by ES mutants that have no effect
at comparable doses. Therefore, the findings may be most
relevant to antiangiogenic effects seen in vivo, when pharma-
cological doses of ES are administered. Moreover, it is possi-
ble that ES may interfere with extracellular matrix assembly
and thereby elicit antiangiogenic effects through this mecha-
nism. The recent description of collagen XVIII expression in
the early frog embryo (Elamaa et al., 2002) is also consistent
with a biological role for ES in normal development.
 -catenin as a target of ES
To investigate the signaling events triggered by ES, we took
advantage of Xenopus embryogenesis, which involves a cas-
cade of inductive events with only a small number of signal
transduction pathways (Harland and Gerhart, 1997). Mi-
croinjection of ES RNA into animal blastomeres of early
embryos resulted in specific developmental abnormalities:
ectopic cement gland formation and suppression of eye de-
velopment. These phenotypes are characteristic of embryos
in which Wnt signaling has been inhibited by overexpres-
sion of GSK3 or partial depletion of  -catenin (Itoh et al.,
1995; Heasman et al., 2000). The hypothesis that ES func-
tions by impinging on Wnt signaling has been supported us-
ing several experimental approaches in both frog embryos
and human cells. The doses of injected ES RNA (2 ng) are
relatively high compared with those typically used for other
signaling proteins in the Xenopus embryos. It is possible that
the requirement for high levels of ES arises from the fact that
mammalian ES is labile in frog cells or that binding of hu-
man ES to its frog receptor is suboptimal.
Several inhibitors of  -catenin signaling are known to in-
hibit dorsal development; however, animal ventral injections
of RNA (Fig. 1) do not allow one to assess dorsal develop-
ment. Therefore, we tested the effect of ES on embryos in-
jected into dorsal vegetal blastomeres that are known to con-
tribute to dorsal development. ES had very little effect on
endogenous axis formation even when injected into dorso-
vegetal blastomeres (data not shown). Thus, ES appears to
affect only the secondary but not the primary body axis. We
note that overexpression of GSK3, a well-characterized in-
hibitor of  -catenin, also has only mild effects on endoge-
nous axis development (He et al., 1995; Pierce and Kimel-
man, 1995; unpublished data). Although the reasons for this
observation are currently unclear, the lack of the effect may
be due to targeting a subcellular pool of  -catenin that is not
directly involved in axis specification (Guger and Gumbiner,
2000). ES would also fail to cause an effect in dorsovegetal
cells if they lack the ES receptor or contain an endogenous
inhibitor. Alternatively, overexpressed ES may function at a
later stage than needed for severe axis disruption or may
have a partial effect on  -catenin.
ES activates a novel molecular pathway leading to
 -catenin degradation
To define at which level ES impinges on Wnt signal trans-
duction, we have shown that ES suppressed axis-inducing
activities of Dsh and  -catenin, yet failed to block the activ-
ity of TVP, a downstream component of the pathway. These
results, obtained in Xenopus embryos and extended to mam-
malian endothelial cells, suggest that ES modulates the Wnt
pathway at the level of  -catenin. Consistent with this hy-
pothesis,  -catenin levels were diminished in the presence of
ES. Interestingly, stabilized  -catenin, which is insensitive to
GSK3-mediated phosphorylation and degradation, was also
affected by ES, indicating that the underlying pathway is
GSK3 independent. Also, ES suppressed  -catenin signaling
in the DLD-1 carcinoma cell line with constitutively high
 -catenin signaling (Morin et al., 1997). This observation is
consistent with our conclusion that ES acts via a novel path-
way and raises an intriguing possibility that ES may have di-
rect antitumor effects.
Among mechanisms regulating  -catenin are stabilization
by the upstream components of the Wnt pathway Dsh, axin,
and GSK3 (Gumbiner, 1997; Salic et al., 2000), or associa-
tion of  -catenin and TCF (Lee et al., 2001), and p53-depen-
dent destruction by Siah1, a mammalian homologue of Sina
(Matsuzawa and Reed, 2001). Our data suggest that ES tar-
gets   -catenin for proteasome-mediated degradation using
pathways independent of  TrCP and Siah1. We also show
that the ES ability to inhibit Wnt signaling depends on glypi-
can 1, since cells infected with a glypican 1 antisense virus fail
to down-regulate TCF reporter activity in response to ES (Fig.
5 C). This result is supported by our recent study showing
that glypicans function as low affinity ES receptors (Karu-
manchi et al., 2001). At present, it remains unclear whether
the requirement of glypicans for ES binding and function is
related to the involvement of glypicans in Wnt signaling (Lin
and Perrimon, 1999; Tsuda et al., 1999; Baeg et al., 2001).
Our data argue that a function of ES is to inhibit Wnt sig-
naling. Interestingly, a list of genes rapidly down-regulated
by ES (Shichiri and Hirata, 2001) includes c-myc, a known
direct target of Wnt signaling (He et al., 1998). Also, we
have shown recently that cyclin D1, another direct target of
Wnt signaling (Shtutman et al., 1999; Tetsu and McCor-
mick, 1999), is repressed by ES, leading to G1 arrest (Hanai
et al., 2002). Moreover, critical cyclin D1 promoter se- Endostatin as a Wnt signaling inhibitor | Hanai et al. 537
quences responsible for ES effects have been mapped to the
LEF/TCF recognition site (Hanai et al., 2002). Together,
these findings support our hypothesis that ES might act by
blocking Wnt/ -catenin signaling.
A role for Wnt signaling in endothelial cells
The Wnt signaling pathway is involved in the control of
multiple cellular processes (Cadigan and Nusse, 1997;
Sokol, 1999; Peifer and Polakis, 2000). In endothelial cells,
Wnt signaling has been reported to increase cell prolifera-
tion (Wright et al., 1999), whereas the secreted Frz-related
protein FrzA has the opposite effect (Dennis et al., 1999;
Duplaa et al., 1999). Moreover, defects of yolk sac and pla-
cental angiogenesis in mice lacking the Frz5 gene directly
demonstrate the involvement of Wnt signaling in vascular
development (Ishikawa et al., 2001). Our results provide
further insight into a possible function of the Wnt/ -cate-
nin pathway in angiogenesis. In particular, our data reveal
that endothelial cell migration and cell cycle progression de-
pend on activation of TCF-responsive target genes. Identifi-
cation and characterization of these targets will be an impor-
tant focus of future studies.
Materials and methods
Reagents and plasmid constructs
The mouse ES protein (ES) and ES mutant (ES3.1) were produced and puri-
fied from yeast as described previously (Dhanabal et al., 1999a; Karuman-
chi et al., 2001). ES cDNA with K-cadherin signal peptide sequence in the
NH2 terminus was amplified by PCR and cloned into pCS2  (Turner and
Weintraub, 1994). An NH2-terminal deletion of ES (ES-m) was generated
by removing aa 22–84 using the primer 5 -AACACCCCCCTGTCTGGATC-
CCTGTTTTCTGGCTC-3  as described (Makarova et al., 2000). TOP/FOP-
FLASH (a gift of H. Clevers, University Medical Center Utrecht, Utrecht,
Netherlands) (van de Wetering et al., 1991, 1996) and pSia-Luc (Fan et al.,
1998) luciferase reporters and expression plasmids for Myc- and Flag-
tagged  -catenin (Yost et al., 1996; Liu et al., 1999), pCS2-Xdsh (Sokol,
1996), and pCS2-TVP (Vonica et al., 2000) have been described previ-
ously. The TVP sequence was subcloned from pCS2-TVP into EcoR1 and
Not1-digested retroviral vector pLXSHD
2 (a gift from D. Miller and A. Kaz-
lauskas, Harvard Medical School, Boston, MA) (Karumanchi et al., 2001),
confirmed by sequencing, and referred to as the TVP retroviral vector. Two
different stabilized constructs of  -catenin were used in this study, the
NH2-terminal deletion construct  N– -catenin (Yost et al., 1996) and the
S A  -catenin mutant (Liu et al., 1999). Flag-Siah1 and Flag-Siah1-dR
(gifts of E. Fearon, University of Michigan Medical School, Ann Arbor, MI)
have been described previously (Hu and Fearon, 1999). Flag- TrCP and
Flag- N TrCP (gifts of N. Matsunami, University of Utah, Salt Lake City,
UT) have also been described (Liu et al., 2001).
Cell culture and DNA transfection
Human umbilical vein endothelial cells (HUVECs) were obtained from
Clonetics. CPAE cells and DLD-1 cells were obtained from American Type
Culture Collection. HUVECs and CPAE cells were used between passages
2 and 3. HUVECs were maintained in EGM2-MV medium (Clonetics) con-
taining endothelial basal medium (EBM-2), supplemented with 5% FBS,
gentamicin, amphothericin B, hydrocortisone, ascorbic acid, and the fol-
lowing growth factors: VEGF, bFGF, hEGF, and IGF-1. CPAE cells were
maintained in DME supplemented with 10% FCS and penicillin/streptomy-
cin (P/S). DLD-1 cells were maintained in RPMI 1640 supplemented with
10% FCS and P/S. All cell lines were grown at 37 C in a 100% humidified
incubator with 5% CO2. Cells were grown to 80–90% confluency, har-
vested with trypsin, and resuspended to the cell density required for each
assay. For transient transfections, 60–70% confluent cells in 6-well plates
were transfected using Lipofectamine 2000 (Life Technologies) for HUVECs
and CPAE cells and Lipofectamine Plus (Life Technologies) for DLD-1
cells. Total amount of transfected DNA in each experimental group was
adjusted to the same value by adding vector DNA. MG132 was purchased
from Sigma-Aldrich.
Retrovirus production
Retrovirus production was performed as described before (Ory et al.,
1996). Briefly, 20  g of retroviral plasmids were transfected into the 293
GPG packing cell line using the Calphos transfection kit (CLONTECH Lab-
oratories, Inc.). 48 h after transfection, the packing cell line supernatant
was collected and used to infect target cells (HUVECs) in complete me-
dium (EGM-2MV).
Xenopus eggs and embryos
Eggs were obtained from Xenopus females injected with 600 U of human
chorionic gonadotropin, fertilized in vitro, and cultured in 0.1  Marc’s
modified Ringer’s medium as described previously (Newport and Kirsch-
ner, 1982). Embryonic stages were determined according to Nieuwkoop
and Faber (1967).
RNA microinjections
Capped synthetic RNAs were generated with SP6 or T7 RNA (Krieg and
Melton, 1984) by in vitro transcription of plasmids using mMessage mMa-
chine kits (Ambion). RNA microinjections were performed as described
(Itoh et al., 1995).
Luciferase assay
After transient transfection of the plasmids, cells were incubated for 20 h in
10% FCS (for the TOP-FLASH and FOP-FLASH promoters), and luciferase
activity in the cell lysates was determined using a luminometer normalized
using sea-pansy luciferase activity under the control of the thymidine kinase
promoter. The Dual-Luciferase Reporter Assay System was purchased from
Promega. For luciferase assays of embryo cell lysate, embryos were injected
in the animal pole with 30 pg of the Siamois-luciferase reporter (pSia-Luc)
DNA (Fan et al., 1998) and mRNAs for ES and ES mutant, and the luciferase
activity was measured in light units as described (Fan and Sokol, 1997).
Immunoprecipitation and immunoblotting
Collected cell lysates or cell lysates immunoprecipitated as described
(Kawabata et al., 1998) were separated by PAGE (precast gels; Bio-Rad Lab-
oratories). This was followed by electroblotting onto a polyvinylidenedifluo-
ride membrane. After blocking with 2% BSA in Tris buffered saline/Tween-
20 (TBS-T) for 1 h, the polyvinylidenedifluoride membrane was incubated
overnight with each primary antibody. After washing with TBS-T, the mem-
brane was incubated with the secondary anti–mouse Ig at a 1:5,000 dilution
for 0.5 h. Protein bands were detected using SuperSignal® West Pico
Chemiluminescent Substrate (Pierce Chemical Co.). Primary antiserum
against ES was used as described (Dhanabal et al., 1999a). Injected embryos
were lysed in 500  l of lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH
7.5, 50 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, 10 mM NaF, 1 mM Na3VO4)
when sibling embryos had developed to late blastula stages (stage 8 ).
Western blot analysis was performed as described (Itoh et al., 1998).
Migration assays
Migration assays were performed using 12-well Boyden chemotaxis cham-
bers (Neuro Probe, Inc.) with a polycarbonate membrane (25   80-mm,
PVD free, 8  m pore size; Osmonics) as described previously (Dhanabal et
al., 1999a). Briefly, polycarbonate membrane coated with Vitrogen 100
(Collagen Biomaterials, Inc.) collagen solution (0.3 mg/ml) on both sides
was placed over a 0.1% gelatin-coated bottom chamber. The lower cham-
ber was filled with DME containing 0.1% BSA and 20 ng/ml bFGF or 20
ng/ml VEGF (R & D Systems) or nothing. The upper chamber was seeded
with 60,000 cells/well with different concentrations of recombinant ES in
triplicate. Endothelial cells were labeled with DiI and allowed to migrate
for 5 h at 37 C as described (Dhanabal et al., 1999a).
Cell cycle analysis
HUVECs were growth arrested by contact inhibition for 48 h. The 0 h
value refers to the percentage of cells in S phase at this time point. Cells
(0.1   10
6 cells/well) were harvested and plated into a 6-well plate in 1%
FCS/EGM2-MV with recombinant VEGF or bFGF with or without ES. The
cells were harvested at various time points and then fixed in ice-cold etha-
nol. Fixed cells were dehydrated at 4 C for 0.5 h in PBS containing 2%
FCS and 0.1% Tween-20 and then centrifuged and resuspended in 0.5 ml
of the same buffer. RNase digestion (5  g/ml) was performed at 37 C for
1 h followed by staining with propidium iodide (5  g/ml). The cells were
analyzed using a FACScan Becton Dickinson flow cytometer.
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